Page 210 - 2019_04-Haematologica-web

G. Fatobene et al.
Table 2. Characteristics of chronic graft-versus-host disease according to alternative donor group.
Characteristics
Chronic GvHD, n. (%) Classic
Overlap
Prior late acute GvHD, n. (%)
Prior II-IV acute GvHD, n. (%)
Time from HCT to diagnosis, months, (range)
NIH severity at diagnosis, n. (%) Mild
Moderate Severe
Type of onset, n. (%)
De novo
Quiescent
Progressive
Sites involved and eosinophilia at onset, n. (%) Skin
Eyes
Mouth
Liver
Lung (bronchiolitis obliterans) Gastrointestinal tract Joint/fasciae
Genitals Eosinophilia
N. of GvHD sites at onset, n. (%) 1or2
3
>3
KPS <80% at onset, n. (%)*
1Cord blood vs. mismatched unrelated. 2Haploidentical vs mismatched unrelated. * Used values within 14 days of onset (pre or posttransplant). KPS at onset available for 66 1- mMUD, 22 UCB and 17 haploidentical related HCT recipients. GVHD: graft-versus-host disease; HCT: hematopoietic cell transplant; NIH: National Institutes of Health; KPS: Karnofsky Performance Status.
Unrelated Umbilical cord mismatched blood
(N=79) (N=29)
P1 Related P2 hploidentical
(N=21)
0.81 4 (19) 0.18 17 (81)
0.35 8 (38) 0.05 0.0008 20 (95) 0.02 0.001 7.5 (2.9-15.4) 0.77
5 (24) 0.74 0.008 11 (52)
5 (24)
0 0.02 0.01 5 (24)
16 (76)
0.05 16 (76) 0.89
0.04 5 (24) 0.23 0.48 16 (76) 0.02 0.01 2 (10) 0.03 0.10 1 (5) 0.05
0.002 6 (29) 0.55 0.17 0 0.24 0.27 1 (5) 0.45 0.01 3 (14) 0.34
13 (62)
0.03 7 (33) 0.02
7 (9) 72 (91)
14 (18)
55 (70) 7.8 (2.7-38.2)
13 (16) 46 (58) 20 (25)
20 (25) 7 (9) 52 (66)
59 (75) 30 (38) 74 (94) 27 (34) 0
28 (35) 5 (6) 8 (10) 19 (24)
26 (33) 31 (39) 22(28)
22 (33)
3 (10) 26 (90)
3 (10)
29 (100) 3.9 (2.6 -18.2)
11 (38) 17 (59) 1 (3)
0
3 (10) 26 (90)
16 (55) 5 (17) 26 (90) 3 (10) 1 (3) 20 (69) 0
1 (3) 1 (3)
16 (55) 11 (38)
2(7) 1(5)
12 (55) 0.08
6 (35) 0.88
Dose of prednisone at onset, n. (%)
None
0.1 - 0.4 mg/kg
0.5–1.0mg/kg 5(13) 1(7) 1(9)
29 (73) 6 (15)
9 (64)
4 (29) 0.19
7 (64)
3 (27) 0.95
Platelets < 105/mL at onset, n. (%) 14 (18) 7 (24) 0.46 2 (10) 0.36
Figure 2. Patterns of organ involvement differ according to the type of alternative donor. The figure shows the proportions of patients with involved sites or signs of chronic graft-versus-host dis- ease at any time from initial diagnosis to last follow-up
according to
donor HCT group. Patients could have more than one site involved. GI, gastroin- testinal; HCT, hematopoietic cell transplant; UCB: umbili- cal cord blood.
alternative
838
haematologica | 2019; 104(4)